Real-time enrollment status for this untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 1:03 PM UTC
| NCT Number | NCT07221149 |
| Recruiting Status | Recruiting |
| Condition | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma |
| Phase | PHASE2 |
| Target Enrollment | 690 participants |
| Active Locations | 34 sites in the US |
| Sponsor | Bristol-Myers Squibb |
| Last Updated on CT.gov | September 30, 2026 (1 week ago) |
As of October 12, 2026: Clinical trial NCT07221149 is currently recruiting participants. This phase2 study for untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma is actively seeking new participants at 34 locations across the United States. The study is sponsored by Bristol-Myers Squibb. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07221149 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 34 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07221149 was last updated 1 week ago (September 30, 2026). HelloStudys verifies this status automatically.